CHO-K1 Cell Line SUMF1 Co-expression for Phosphorylated GALNS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing lysosomal sulfatase enzymes for treating lysosomal storage diseases face challenges in achieving high yields of active, highly phosphorylated enzymes due to inefficient secretion and immunogenicity issues, leading to the need for high doses and potential increased immunogenicity.
Innovation Solution
Engineering a CHO-K1 cell line derivative (G71) to express recombinant human sulfatase modifying factor 1 (SUMF1), resulting in high yields of active, highly phosphorylated recombinant lysosomal sulfatase enzymes by preventing loss to the lysosomal compartment, using an END3 complementation group cell line that co-expresses SUMF1 and N-acetylgalactosamine-6-sulfatase (GALNS).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional mammalian cell lines are used to produce lysosomal sulfatase enzymes, then the enzymes can be secreted into the growth medium, but the yield of active, highly phosphorylated enzymes is low and immunogenicity is high
Solution Approach 1:
The patent modifies the cellular environment and enzymatic parameters by introducing SUMF1 expression to enhance formylglycine generation, adjusting phosphate buffer conditions (pH 5.0-6.0, 25-100mM concentration), and optimizing temperature (37°C) to achieve high levels of phosphorylation and activity while reducing immunogenicity
Solution Approach 2:
The patent uses SUMF1 (sulfatase modifying factor 1) as an intermediary enzyme that catalyzes the conversion of cysteine to formylglycine in the sulfatase enzyme, enabling efficient phosphorylation and activation without direct harmful interactions that would increase immunogenicity
2Reliability
If high doses of enzyme are administered to treat lysosomal storage diseases, then treatment effectiveness is improved, but immunogenicity increases
Solution Approach 1:
The patent optimizes enzyme parameters including phosphate buffer concentration (25-100mM), pH (5.0-6.0), and temperature (37°C) to maximize enzyme activity and stability, allowing lower doses to achieve the same therapeutic effect and thereby reducing immunogenicity
3Productivity
If lysosomal enzymes are directed to the lysosome in normal cells, then the enzymes fulfill their degradation function, but secretion into the growth medium is reduced
Solution Approach 1:
The patent employs SUMF1 as an intermediary that facilitates the post-translational modification of sulfatase enzymes, enabling efficient phosphorylation and activation while maintaining compatibility with both intracellular and extracellular environments, thus achieving high secretion efficiency without compromising enzyme activity
Solution Approach 2:
The patent optimizes cellular and biochemical parameters including phosphate buffer conditions, temperature, and enzymatic activity to achieve high levels of phosphorylation and secretion while maintaining enzyme functionality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of therapeutically effective, high-yield, active lysosomal sulfatase enzymes for enzyme replacement therapy, improving targeting efficiency and reducing immunogenicity, thereby enhancing treatment efficacy for lysosomal storage diseases.
Implementation Method 1
Lysosomal enzymes constitute a separate class of glycoproteins defined by phosphate at the 6-position of terminal mannose residues
Implementation Method 2
The cysteine to FGly post-translational enzyme activation occurs within the endoplasmic reticulum on unfolded sulfatases immediately after translation
Implementation Method 3
Mannose-6-phosphate is bound with high affinity and specificity by a receptor found on the surface of most cells
Data Source
AI summary
This invention provides compositions of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase (GALNS), and pharmaceutical compositions and formulations thereof, methods of producing and purifying GALNS, and its use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the GALNS enzyme, e.g., Mucopolysaccharidosis IVa (MPS IVa or Morquio A syndrome).